The role of axillary lymph node dissection in breast cancer patients has lo
ng been the subject of controversial discussion,The reason for this is that
the removal of axillary lymph nodes is associated with high morbidity and
is of little value for long-time prognosis. With the introduction of sentin
el node biopsy, a new minimal invasive procedure is now at the stage of cli
nical evaluation. This new technique seems to predict axillary status with
high accuracy by removal of a single representative lymph node. Patients wi
th negative axillary status might be spared complete axillary dissection. D
ue to a number of unsolved technical details and a remarkable learning curv
e for individual surgeons, sentinel node biopsy should not be introduced as
a clinical standard before questions of patient selection, training, and q
uality control have been solved.